Conference Proceedings
Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
Michael Hofman, John A Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy J Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Kaur Sandhu
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Abstract
228 Background: Lutetium-177 (177Lu)-PSMA-617 (LuPSMA) is a radiolabelled small molecule that binds with high affinity to prostate specific membrane antigen (PSMA) enabling targeted delivery of beta-radiation. We have previously reported favourable activity with low toxicity in a 30 patient study in men with metastatic castrate-resistant prostate cancer (mCRPC) and now report updated results including a twenty patient extension cohort. Methods: In this phase II trial, 50 pts with PSMA-avid mCRPC who had progressed after standard therapies received up to 4 cycles of LuPSMA every 6 weeks. The primary endpoints were PSA response (PCWG2) and toxicity (CTCAE v4). Other endpoints included imaging..
View full abstract